Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy.

John G. Evans-Jones; Lucy E. Cottle; David J. Back; Sara Gibbons; Nicholas Beeching; Peter B. Carey; Saye H. Khoo

doi:10.1086/652149

Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy.

John G. Evans-Jones
, Lucy E. Cottle
, David J. Back
, Sara Gibbons
, Nicholas Beeching
, Peter B. Carey
, Saye H. Khoo

Research output: Contribution to journal › Article › peer-review

79 Citations (Scopus)

Abstract

We assessed the risk of clinically significant drug interactions in patients receiving antiretrovirals, and their recognition by physicians. Clinically significant drug interactions were recorded in 27% of 159 patients, with 15% of interactions potentially lowering antiretroviral concentrations. Risk of clinically significant drug interactions was significantly related to receipt of protease inhibitors. Only 36% of clinically significant drug interactions were correctly identified by physicians.

Original language	English
Pages (from-to)	1419-1421
Number of pages	3
Journal	Clinical Infectious Diseases
Volume	50
Issue number	10
DOIs	https://doi.org/10.1086/652149
Publication status	Published - 15 May 2010
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1086/652149

Cite this

@article{5fc1e7b13528473fa80984a0c4059df8,

title = "Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy.",

abstract = "We assessed the risk of clinically significant drug interactions in patients receiving antiretrovirals, and their recognition by physicians. Clinically significant drug interactions were recorded in 27\% of 159 patients, with 15\% of interactions potentially lowering antiretroviral concentrations. Risk of clinically significant drug interactions was significantly related to receipt of protease inhibitors. Only 36\% of clinically significant drug interactions were correctly identified by physicians.",

author = "Evans-Jones, \{John G.\} and Cottle, \{Lucy E.\} and Back, \{David J.\} and Sara Gibbons and Nicholas Beeching and Carey, \{Peter B.\} and Khoo, \{Saye H.\}",

year = "2010",

month = may,

day = "15",

doi = "10.1086/652149",

language = "English",

volume = "50",

pages = "1419--1421",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "10",

}

TY - JOUR

T1 - Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy.

AU - Evans-Jones, John G.

AU - Cottle, Lucy E.

AU - Back, David J.

AU - Gibbons, Sara

AU - Beeching, Nicholas

AU - Carey, Peter B.

AU - Khoo, Saye H.

PY - 2010/5/15

Y1 - 2010/5/15

N2 - We assessed the risk of clinically significant drug interactions in patients receiving antiretrovirals, and their recognition by physicians. Clinically significant drug interactions were recorded in 27% of 159 patients, with 15% of interactions potentially lowering antiretroviral concentrations. Risk of clinically significant drug interactions was significantly related to receipt of protease inhibitors. Only 36% of clinically significant drug interactions were correctly identified by physicians.

AB - We assessed the risk of clinically significant drug interactions in patients receiving antiretrovirals, and their recognition by physicians. Clinically significant drug interactions were recorded in 27% of 159 patients, with 15% of interactions potentially lowering antiretroviral concentrations. Risk of clinically significant drug interactions was significantly related to receipt of protease inhibitors. Only 36% of clinically significant drug interactions were correctly identified by physicians.

U2 - 10.1086/652149

DO - 10.1086/652149

M3 - Article

SN - 1058-4838

VL - 50

SP - 1419

EP - 1421

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 10

ER -

Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy.

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this